Researchers assessed the feasibility of using large language models to match cancer patients with certain genetic mutations to appropriate clinical trials.
A multicenter, single-arm, phase 2 trial investigated the activity and safety of varnimcabtagene autoleucel in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
In terms of locoregional recurrence, risk remains low when patients are treated with RT tailored to their individual risk.
In this phase 3 trial, researchers sought to determine whether the combination of ceralasertib plus durvalumab would improve NSCLC outcomes compared to docetaxel.
Umbilical cord blood stem cell microtransplantation combined with chemotherapy significantly prolonged disease-free survival (DFS) in patients with acute myeloid leukemia (AML) and high-risk ...
Elevated respiratory pulse envelope amplitudes (AF RPE) independently distinguished primary central nervous system lymphoma (PCNSL) from healthy states and are associated with mortality, supporting ...
ART can safely replace ALND, with no axillary recurrences, and fewer cases of lymphedema in patients with breast cancer.
Investigators developed and validated new PSMA-PET-based nomograms for prognostication across prostate cancer stages to help guide management.
Investigators sought to identify risks of prescription drug promotion by social media influencers and how current evidence can inform future research and effective policy ...
LGBTQ+ cancer survivors and their caregivers frequently encounter "minority stress" and suboptimal communication within oncology settings, according to a secondary analysis of the FOCUS Study ...
Investigators sought to determine whether weight-based dosing of pembrolizumab could produce outcomes similar to standard fixed dosing for patients with NSCLC.
Researchers compared time from radiographic report to biopsy, oncology visit, and treatment before and after implementation of a computationally assisted navigation referral method.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results